Form 4: Pfizer CEO Albert Bourla Exercises Stock Appreciation Rights

Pfizer's Chairman and CEO, Albert Bourla, reported the exercise of stock appreciation rights and subsequent share dispositions for tax and exercise price obligations.

Summary

• Albert Bourla, Chairman and CEO of Pfizer Inc., exercised 491,626 Stock Appreciation Rights (SARs) on February 25, 2026, which resulted in the acquisition of 491,626 shares of common stock at an exercise price of $33.82 per share.
• Concurrently, 8,303 shares were disposed of at $27.09 per share to satisfy tax obligations related to the SAR earn-out.
• An additional 467,241 shares were disposed of at $26.92 per share to cover the exercise price of the SARs.
• Following these transactions, Bourla directly holds 388,671 shares of Pfizer common stock and indirectly holds 6,003 shares through a Rule 16b-3 Plan.
• The settlement price for the SARs was based on the 20-day average of Pfizer common stock closing prices ending on the settlement date.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, representing a routine executive compensation transaction that does not indicate a significant positive or negative shift in company fundamentals or insider sentiment.

Positives

• The exercise of Stock Appreciation Rights indicates a vesting event and a realization of value for the CEO, reflecting past performance or tenure.
• The CEO continues to hold a significant number of shares (388,671 direct, 6,003 indirect), maintaining alignment with shareholder interests.

Negatives

• A substantial number of shares (475,544 shares total) were disposed of to cover tax obligations and the exercise price, which reduces the CEO's direct ownership stake from the exercised amount.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding Pfizer's future outlook.

Industry Context

StockSavvy.ai notes that executive compensation, particularly through equity-based awards like Stock Appreciation Rights, is a standard practice across the pharmaceutical industry. The exercise and subsequent sale of shares for tax and exercise price purposes are routine events for executives realizing value from their compensation plans. This filing reflects a typical compensation event rather than a strategic shift or a unique industry trend.

Comparison to Industry Standards

• StockSavvy.ai finds that the structure of executive equity compensation, involving the exercise of SARs and subsequent share withholdings for taxes and exercise costs, is a common and widely accepted practice among large-cap pharmaceutical companies.
• For instance, executives at companies like Johnson & Johnson or Merck & Co. frequently report similar transactions as part of their long-term incentive plans.
• The specific values and number of shares are commensurate with the compensation packages typically offered to CEOs of major global pharmaceutical firms, aligning with general industry benchmarks for executive reward realization.

Related Party Transactions

• The transactions reported are related party dealings between the company and its CEO as part of his compensation plan, which is a standard disclosure for executive equity awards.

Stakeholder Impact

• Shareholders: Minimal direct impact as these are routine compensation events. The CEO maintains a significant ownership stake, aligning interests.
• Employees, Customers, Suppliers, Creditors: No direct impact from this specific filing.

Key Dates

Recommendation

This Form 4 filing details a routine executive compensation event involving the exercise of Stock Appreciation Rights and subsequent share dispositions for tax and exercise costs. Such transactions are common and generally do not provide new material information that would warrant a change in investment recommendation. The CEO continues to hold a substantial number of shares, maintaining alignment with shareholder interests. Therefore, a 'hold' recommendation is appropriate as this filing does not present a catalyst for a 'buy' or 'sell' decision.

Keywords

Pfizer, PFE, Albert Bourla, SEC Form 4, Insider Trading, Stock Appreciation Rights, SARs, Executive Compensation, Share Ownership, Director, CEO